GENFIT (NASDAQ:GNFT) Shares Down 0.4% – Should You Sell?

Shares of GENFIT S.A. Unsponsored ADR (NASDAQ:GNFT) fell 0.4% during trading on Monday . The stock traded as low as $4.37 and last traded at $4.71. 56,843 shares traded hands during mid-day trading, an increase of 245% from the average session volume of 16,466 shares. The stock had previously closed at $4.73.

Analyst Ratings Changes

GNFT has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d)” rating on shares of GENFIT in a research report on Tuesday, October 14th. HC Wainwright reduced their target price on GENFIT from $9.00 to $7.00 and set a “buy” rating for the company in a report on Wednesday, September 24th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $7.00.

GENFIT Stock Performance

The company has a debt-to-equity ratio of 0.09, a current ratio of 3.74 and a quick ratio of 3.74. The firm’s 50-day simple moving average is $4.43 and its 200 day simple moving average is $4.12.

Hedge Funds Weigh In On GENFIT

An institutional investor recently bought a new position in GENFIT stock. OLD Mission Capital LLC acquired a new stake in shares of GENFIT S.A. Unsponsored ADR (NASDAQ:GNFT) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 22,238 shares of the company’s stock, valued at approximately $76,000. Institutional investors own 2.24% of the company’s stock.

GENFIT Company Profile

Genfit is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies and diagnostics for serious metabolic and inflammatory liver diseases. Founded and headquartered in Lille, France, the company has concentrated its efforts on nonalcoholic steatohepatitis (NASH), an area of significant unmet medical need. By combining expertise in molecular biology, chemistry and medical imaging, Genfit aims to deliver products that can both treat disease and improve diagnosis and monitoring of liver conditions.

The company’s lead therapeutic candidate, elafibranor (GFT505), is a first-in-class, dual PPAR alpha/delta agonist designed to address the underlying metabolic and inflammatory processes that drive NASH.